Myriad Genetics, Inc. (MYGN)
After hours:
| Previous Close | 27.85 |
| Open | 28.27 |
| Bid | 27.61 x 600 |
| Ask | 27.67 x 300 |
| Day's Range | 27.21 - 28.27 |
| 52 Week Range | 13.82 - 28.90 |
| Volume | |
| Avg. Volume | 865,270 |
| Market Cap | 2.503B |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast CancerSALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer Edition, which revealed that a majority (63%) of women do not know that there is an increased risk of breast cancer for women with dense breast
- GlobeNewswire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testin
- GlobeNewswire
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent no. 12,024,749, entitled “Combinatorial DNA Screening,” covers Myriad’s groundbreaking platform MRD technology, which enable
